HOME >> BIOLOGY >> NEWS
Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients

Marimastat, a matrix metalloproteinase inhibitor, offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects, reports an international team of researchers from the United States and Britain.

The randomized clinical trial compared the effects of three different doses of marimastat with the chemotherapy drug gemcitabine in 414 patients with advanced pancreatic cancer. During this clinical trial, gemcitabine was approved for use in pancreatic cancer, and is now considered the standard of care.

According to the study, the one-year survival rate for patients with localized cancer was 20 percent for patients given the highest dose of marimastat and 19 percent for patients treated with gemcitabine. Although patients taking gemcitabine reported greater improvements in pain and mood, fewer toxic side effects (e.g., pulmonary complications and nausea) were reported in patients taking marimastat versus gemcitabine (12 percent versus 22 percent, respectively).

Marimastat did not show benefit in lower doses or in patients with metastatic pancreatic cancer. The one-year survival rate for patients taking lower doses of marimastat was 14 percent.

Researchers say marimastat appears to benefit some non-metastatic patients and suggest the agent be tested in those patients in combination with gemcitabine. "Five years ago, patients with advanced pancreatic cancer did not have any good treatment options, but gemcitabine and newly engineered drugs like marimastat are giving us hope," says the study leader Simon Bramhall, from the Queen Elizabeth Hospital, Birmingham, England. "These clinical trial results are encouraging and suggest that targeted molecular therapy may benefit some patients."

Matrix metalloproteinase inhibitors restrict the growth and spread of solid tumors by blocking blood vessel growth to the site of tumors. Marimastat is also being tested in ovarian a
'"/>

Contact: Carrie Bittman
bittmanc@asco.org
703-299-1016
American Society of Clinical Oncology
30-Jul-2001


Page: 1 2

Related biology news :

1. Genetic modification of linseed produces healthier omega 3 and 6 fatty acids
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
4. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
5. First genetic comparison of purebred domestic dogs produces surprises
6. Biological computer diagnoses cancer and produces drug in a test tube
7. High-fat fast-food breakfast produces rush of inflammatory factors into blood stream, UB study finds
8. Oil exploitation in Ecuadors Amazon basin produces a public health emergency
9. Method produces uniform, self-assembled nanocells
10. Scientists develop plant that produces potential anti-carcinogen
11. Brains master molecule produces same behavior in mice from three different psychostimulant drugs

Post Your Comments:
(Date:4/22/2014)... to Asia to coordinate with allies and reconfirm ... the Office of Naval Research (ONR) emphasized today ... an example of strong and growing ties between ... region. , The APTEP program, centered in Hawaii ... development of alternative energy technologies. It takes a ...
(Date:4/22/2014)... French . ... the complete genome and subsequent phylogenetic analysis show that ... that is distinct from strains previously identified in the ... also linked the laboratory confirmed cases with the initial ... virus is a lethal, highly contagious virus for which ...
(Date:4/22/2014)... that exposure to environmental enrichment can induce ... learning and memory. Previous studies have demonstrated ... the superficial layer of the cerebral cortex ... and these neurons exhibit very weak properties ... Whether environmental enrichment has an impact on ...
Breaking Biology News(10 mins):Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
Cached News: